Celestia S. Higano, MD, FACP

Articles by Celestia S. Higano, MD, FACP

Dr. Higano on the State of Immunotherapy in Prostate Cancer

May 7th 2020

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

ByE. David Crawford, MD,Neal Shore, MD, FACS,Celestia S. Higano, MD, FACP,Anders Neijber, MD, PhD, MBA,Vladimir Yankov, MD

January 3rd 2016

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

Celestia S. Higano, MD, FACP

Articles by Celestia S. Higano, MD, FACP

Dr. Higano on the State of Immunotherapy in Prostate Cancer

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

Latest Updated Articles

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers